At the news
? BULLISHIMPACT 7/10 DEFM14A filed Sep 4, 2026 at 17:23 ET
BioLife Solutions (BLFS) is seeking stockholder approval for its acquisition by Repligen Corporation (RGEN) in a cash-and-stock deal offering $11.25 cash plus 0.1442 RGEN shares per BLFS share. The BioLife board unanimously recommends voting FOR, with the special meeting scheduled for October 5, 2026. If approved, the merger is expected to close in Q4 2026, and BLFS stockholders will own approximately 11.1% of the combined company.
- Merger consideration: $11.25 cash + 0.1442 shares of Repligen common stock per BioLife share
- Implied value per BioLife share: $31.00 as of July 21, 2026 (pre-announcement) and $36.19 as of September 2, 2026
- BioLife stockholders will own approximately 11.1% of Repligen post-merger
- Special meeting: October 5, 2026; vote requires majority of outstanding shares
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access